Genetics Institute suspends phase II study of rhiL-12.
D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D018664:Interleukin-12 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D018664:Interleukin-12